Patent SG-11201909064R-A (SG)
Title: Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
Inventor: ZIMMERMANN ASTRID
IPC: A61K31/5386
Filed: 2018-03-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT 011101 V III °nolo olommonmoiloiflo VII IE (10) International Publication Number WO 2018/178040 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 31/5386 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) A61K 31/519 (2006.01) A61N 5/00 (2006.01) A61K 31/5377 (2006.01) (21) International Application Number: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 17163837.2 17204926.4 PCT/EP2018/057708 27 March 2018 (27.03.2018) English English 30 March 2017 (30.03.2017) EP 01 December 2017 (01.12.2017) EP (71) Applicants: MERCK PATENT GMBH [DE/DE]; Frank- furter Strasse 250, 64293 Darmstadt (DE). PFIZER INC. [US/US]; 235 East 42nd Street, NEW YORK, NY 10017 (US). (72) Inventors: ZIMMERMANN, Astrid; Pfaffengasse 12, 64367 MUEHLTAL (DE). DAMSTRUP, Lars; Jesper- vej 100, 3400 HILLEROED (DK). PROKEIN, Anne- Kathrin; Bluetenweg lc, 64380 ROSSDORF (DE). (74) Agent: VALLAZZA, Marco; Merck Serono Sa Intellectu- al Property, c/o Merck Patent GmbH, 64271 DARMSTADT (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMBINATION OF AN ANTI-PD-Ll ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CAN- CER (57) : The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L antibody and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-Ll expression. 1-1 O 71- O 00 N 1-1 00 1-1 O C